- 121.2k views
Medical management of GI Neuroendocrine tumor
The medical management of gastrointestinal neuroendocrine tumors (GI NETs) involves a comprehensive approach tailored to the specific characteristics of the tumor and the individual patient. For well-differentiated, low-grade tumors that exhibit hormone hypersecretion, somatostatin analogs such as octreotide and lanreotide are commonly used. These agents help control symptoms related to excess hormone production and may also exert antiproliferative effects. Targeted therapies play a significant role in the management of advanced GI NETs. Everolimus, an mTOR inhibitor, and sunitinib, a tyrosine kinase inhibitor, are often employed to inhibit pathways involved in tumor growth and angiogenesis. Peptide receptor radionuclide therapy (PRRT), using radiolabeled somatostatin analogs such as lutetium-177 DOTATATE, has shown efficacy in slowing tumor progression and providing symptom relief.
About the Speaker

Dr. Mohanad Diab
Consultant Medical Oncologist, Burjeel Hospital, AUH